Valeant Canada LP-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Valeant Canada LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013331
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical company that manufactures, markets and distributes pharmaceutical products. The company offers its products in various therapeutic areas, including pain management, neurology, cardiovascular disease, and dermatology. Its products include aczone, aldara, benzaclin, biacna, dermatix ultra, dermatop, dermatop II, efudex, elidel, glumetza, lodalis, loprox, nitoman, noritate and ovita, among others. Valeant Canada markets its products to pharmacies, healthcare practices and hospitals. The company operates manufacturing facilities in Manitoba, Ontario and Quebec. Valeant Canada is headquartered in Laval, Quebec, Canada.

Valeant Canada LP – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Valeant Canada LP, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Valeant Canada LP, Medical Devices Deals, 2011 to YTD 2017 9
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Valeant Canada LP, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 11
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 12
Partnerships 13
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 13
Licensing Agreements 14
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 14
Acquisition 15
Valeant Canada Acquires CROMA Pharma Canada 15
Valeant Canada LP – Key Competitors 16
Valeant Canada LP – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Legal and Regulatory 18
Apr 05, 2016: Valeant Canada: COLD-FX Lawsuit Media Statement 18
Other Significant Developments 19
Jun 13, 2016: Valeant Canada announces an investment of $10 million in Laval facility to increase and secure its export capacity 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Valeant Canada LP, Pharmaceuticals & Healthcare, Key Facts 2
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Valeant Canada LP, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Valeant Canada LP, Deals By Therapy Area, 2011 to YTD 2017 8
Valeant Canada LP, Medical Devices Deals, 2011 to YTD 2017 9
Valeant Canada LP, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 11
Valeant Canada Acquires Dermatology Products from Valeo Pharma for USD23 Million 12
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 13
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 14
Valeant Canada Acquires CROMA Pharma Canada 15
Valeant Canada LP, Key Competitors 16
Valeant Canada LP, Other Locations 17

★海外企業調査レポート[Valeant Canada LP-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • City National Wealth Management:企業の戦略・SWOT・財務分析
    City National Wealth Management - Strategy, SWOT and Corporate Finance Report Summary City National Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • EQT Corporation (EQT):石油・ガス:M&Aディール及び事業提携情報
    Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas, natural gas liquids (NGL), ethane and crude oil. EQT provides gathering, transmissio …
  • DePuy Synthes Inc:医療機器:M&Aディール及び事業提携情報
    Summary DePuy Synthes Inc (DePuy Synthes), a subsidiary of Johnson & Johnson, is a medical device company that provides products for orthopedic and neurological procedures. DePuy Synthes operates through eight divisions: joint reconstruction, sports medicine, neurological, spine, trauma, cranio-maxi …
  • Ashtead Group Plc (AHT):企業の財務・戦略的SWOT分析
    Ashtead Group Plc (AHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Newfoundland and Labrador Hydro:企業の戦略的SWOT分析
    Newfoundland and Labrador Hydro - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Agilent Technologies Inc (A)-製薬・医療分野:企業M&A・提携分析
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • Inova Health System:企業の戦略的SWOT分析
    Inova Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Owens & Minor Inc (OMI)-製薬・医療分野:企業M&A・提携分析
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • Skyhawk Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Skyhawk Therapeutics Inc (Skyhawk) is a biotechnology company that discovers, develops and commercializes small molecule medicines that correct RNA expression. The company harnesses its STAR (Small molecule Therapies for Alternative splicing in RNA) platform, which combines information from …
  • Mentor Worldwide LLC:企業の戦略的SWOT分析
    Mentor Worldwide LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • ICA Gruppen AB:企業の戦略・SWOT・財務情報
    ICA Gruppen AB - Strategy, SWOT and Corporate Finance Report Summary ICA Gruppen AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Genticel SA (GTCL)-製薬・医療分野:企業M&A・提携分析
    Summary Genticel SA (Genticel), formerly BT Pharma, is a biopharmaceutical company that develops therapeutic vaccines for women infected by the human papillomavirus. The company provides pipeline products including ProCervix, a bivalent HPV therapeutic vaccine candidate and multivalent candidate vac …
  • American Axle & Manufacturing Holdings, Inc.:企業の戦略・SWOT・財務分析
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Shield Therapeutics Plc (STX):企業の財務・戦略的SWOT分析
    Summary Shield Therapeutics Plc (Shield Therapeutics) is a specialty pharmaceutical company that focus on the development and commercialization products for the treatment of anaemia associated with renal and gastrointestinal disorders. The company’s product portfolio includes Feraccru, a stable, non …
  • Arafura Resources Ltd:企業の戦略・SWOT・財務情報
    Arafura Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Arafura Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Galectin Therapeutics Inc.:企業のM&A・事業提携・投資動向
    Galectin Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Galectin Therapeutics Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Exor N.V
    Exor N.V - Strategy, SWOT and Corporate Finance Report Summary Exor N.V - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nevada Gold & Casinos, Inc.:企業の戦略・SWOT・財務分析
    Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆